Diligence memo · auto-generated · as of July 2, 2026
Zomedica Pharmaceuticals Corp.
Zomedica Pharmaceuticals Corp. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Zomedica Pharmaceuticals Corp. operates in Pharmaceuticals, based in ANN ARBOR.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Zomedica Pharmaceuticals Corp. has raised $26M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2019-05-10.
Most recent recorded round closed around 2019-05-10.
Valuation (modeled)modeled
Provath models Zomedica Pharmaceuticals Corp. at approximately $372M (range $14M–$2.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.44× the median modeled value of Series A Pharmaceuticals companies in 2019–2021 (76 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 7.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 21.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 70% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 78% of those peers.
Closest niche peers: Xynomic Pharmaceuticals Holdings, Inc., Honest Globe Inc., Athenen Therapeutics, Inc., CerSci Therapeutics Inc., Rational Vaccines, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.